To unmask the alarming prevalence, intricate antimicrobial resistance patterns, and consequential clinical outcomes of World Health Organization (WHO) priority pathogens causing device-associated infections in critical care settings - a frontier analysis of silent pandemic threatening modern healthcare. This groundbreaking retrospective study analysed data from 5,398 patients at risk for central line-associated bloodstream infections (CLABSI) and 15,416 patients for catheter-associated urinary tract infections (CAUTI) spanning 2021-2024. Microbial isolates were categorized according to WHO's priority pathogen classifications. Antimicrobial susceptibility profiles were comprehensively analysed using Clinical and Laboratory Standards Institute guidelines, with statistical analyses elucidating pathogen distribution dynamics, resistance mechanisms, and mortality correlations. Striking findings revealed WHO priority pathogens dominated the microbial landscape, constituting 76.47% of CLABSI and 82.14% of CAUTI isolates - with critical priority organisms overwhelmingly predominant (83.34% and 91.3%, respectively). Carbapenem-resistant Enterobacterales (CRE) emerged as the formidable leading threat (39.5% of CLABSI, 72.7% of CAUTI), while Carbapenem-resistant Acinetobacter baumannii (CRAB) demonstrated exceptional virulence with devastating mortality (93.33%). The study unveiled unprecedented levels of multidrug resistance, with most therapeutic options rendered ineffective; only colistin maintained universal efficacy against gram-negative isolates despite its concerning toxicity profile. Dramatic disparities in infection outcomes revealed CLABSI-associated mortality rates (71.79%) significantly eclipsed CAUTI (39.13%), establishing infection type as a critical independent predictor of survival. This landmark investigation exposes the crossroad between WHO priority pathogens and healthcare-associated infections, sounding an urgent alarm for global healthcare systems. Our findings provide crucial evidence-based guidance for recalibrating therapeutic approaches, optimizing antimicrobial selection, and prioritizing infection control measures in intensive care settings worldwide.
23 January 2026 in World Journal of Microbiology and Biotechnology
Blood stream infections (BSI) are one of the serious and life threatening complications associated with high morbidity and mortality. Identification of patients without bacterial infections is an important component of antimicrobial stewardship. With the advances in the automated blood culture systems especially with the continuous monitoring systems, time to positivity (TTP) of blood cultures has been reduced drastically thereby allowing faster de-escalation of the antibiotics.: In this study, we have analysed the TTP of different bacterial isolates, and the effects of initiation of antimicrobials and blood volume on TTP. Adult patients with monomicrobial bacteraemia in an academic hospital were included retrospectively over a four-year period. Time to positivity was recorded for each positive sample. Information about the timing of blood sample collection i.e. before or after start of antibiotics was collected from the blood culture requisition form. The blood volume in the blood culture bottle is the virtual blood volume given by the Bact-Alert Virtuo instrument. A total of 38,606 blood culture samples that flagged positive from adult patients with suspected BSIs were included. 79% of the samples had a TTP of less than 24 hours and 15% of the samples had TTP of 24 to 48 hrs. Only 6% of the samples had TTP of more than 48 hours. Gram negative pathogens (Average TTP- 12.5hours) have shorter TTP when compared to Gram positive pathogens (Average TTP- 15.4 hours).With the use of modern automated blood culture systems, TTP can be used as a tool to guide the antimicrobial therapy and early de-escalation of the empirical antibiotics thereby reducing the emergence of antimicrobial resistance.
15 September 2024 in Indian Journal of Microbiology Research
Secondary bloodstream infections (BSIs) remain one of the frequent and life-threatening complications among COVID 19 infected patients. The present study has been undertaken to determine the prevalence of secondary BSIs in patients with COVID-19 This is an observational case control study, conducted between May2020 and April 2021 in a tertiary care centre in South India. The study population were further divided into three groups—one case group (COVID group), and two control (non-COVID group 2020-21 and 2019-20). Blood cultures sent from a suspected care of secondary blood stream infection were processed and outcomes like blood culture positivity rate, clinically relevant growth, contaminant rate and multidrug resistant organism rate were compared between the COVID group and non-COVID control groups. Among the COVID group 307 (17%) of the episodes were found to show clinically relevant growth compared with 3570 (15.4%) in control group 2020-21 (p<0.05) and 3974(12%) in control group 2019-20 (p<0.001). In all the 3 groups, gram negative bacterial infections were found to be the majority with 50% (COVID group), 57% and 58% (non-COVID groups). Among all the MDR organisms isolated from the COVID group of patients, carbapenem resistant contributes about 88%. In COVID-19 patients, the prevalence of secondary bacterial sepsis due to multidrug resistant organisms are higher when compared to non-COVID patients. Non-adherence to strict infection control practices are the possible causes for the higher infection rate among the COVID group of patients.